Back to Search
Start Over
Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer.
- Source :
- BJU International; May2010, Vol. 105 Issue 10, p1372-1376, 5p, 4 Charts, 1 Graph
- Publication Year :
- 2010
-
Abstract
- Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To report the long-term outcome of high-grade prostate cancer treated with radical prostatectomy (RP) as initial monotherapy, analyse the effect of clinical and pathological variables on survival, and report cancer-related symptoms. PATIENTS AND METHODS A retrospective chart review was conducted to identify patients with Gleason 8–10 prostate cancer found on pathological review in men undergoing RP as initial therapy for clinically localized disease between 1988 and 2005. Kaplan-Meier analysis was used to calculate event-free survival. Univariable and multivariable analyses were used to assess the effects of clinical and pathological variables on prostate-specific antigen (PSA) recurrence. RESULTS After excluding 20 patients, 119 were identified with pathologically confirmed high-grade cancers at the time of RP. The overall median (interquartile range) follow-up was 73 (41–113) months. Twenty-four (20%) patients had organ-confined cancer, 60 (50%) had specimen-confined cancer, and 14 (12%) had nodal metastasis. Kaplan-Meier analysis showed overall survival rates at 5 and 10 years, respectively, of 90% and 75%, cancer-specific survival of 92% and 82%, and a PSA recurrence-free follow-up at 5 years of 31%. Using univariable analysis, preoperative PSA level, pathological Gleason score, pathological stage, surgical margin status and tumour volume were found to significantly affect the PSA recurrence-free follow-up. No variables were significant on multivariable analysis. Cancer-related symptoms were reported by only 14 patients, with a median time from surgery to first symptom of 43 months. CONCLUSION High-grade prostate cancer can be treated with RP as initial monotherapy with an acceptable 10-year cancer-specific survival (82%). The PSA recurrence-free follow-up is poor (31% at 5 years). However, few patients progress to symptomatic recurrence after PSA relapse within the first 5 years. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14644096
- Volume :
- 105
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- BJU International
- Publication Type :
- Academic Journal
- Accession number :
- 49751431
- Full Text :
- https://doi.org/10.1111/j.1464-410X.2009.08979.x